Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2082324 | Drug Discovery Today: Disease Models | 2006 | 10 Pages |
Abstract
Disorders of myelination are multifaceted and often complex. Animal models cannot, in most cases, mimic the entire complexity of these diseases. This, however, may be neither necessary nor always helpful. Rather, the choice of an appropriate animal model should be based on the pathogenic facet to be studied and the therapeutic approach to be evaluated for tackling a specific disease component. Based on this hypothesis, this review examines the impact of various animal models on the preclinical validation of novel cell and gene therapy strategies for the treatment of myelin disease.
Section editor:Wolfgang Wurst – Institute of Developmental Genetics, GSF Research Centre, Neuherberg, Germany
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Tanja Schmandt, Gudrun Goßrau, Thomas Kischlat, Thoralf Opitz, Oliver Brüstle,